WEDNESDAY, Sept. 5 (HealthDay News) — Stop-and-start hormone-deprivation therapy for localized prostate cancer doesn’t shorten overall survival compared to continuous treatments, andyields fewer side effects such as impotence and hot flashes, a large new study suggests.
A team of Canadian, British and American researchers found that intermittent hormone treatments — which suppress circulating male hormones such as testosterone that “feed” prostate tumors — don’t increase the risk of disease progression. Intermittent treatment also doesn’t increase the chances that patients whose prostate-specific antigen (PSA) levels are slowly rising will eventually die from prostate cancer. Read full article.
